EVolution Therapeutics develops exosome-based therapeutics to actively enhance wound healing in patients with non-healing wounds, addressing a significant healthcare burden that costs the NHS £5.6 billion annually. By harnessing bio-active molecules from immunologically derived extracellular vesicles, the company aims to shift treatment from passive management to targeted therapeutic intervention for inflammatory diseases.
Funding
Funding not disclosed
Founders
Product
Problem
Non-healing wounds represent a substantial healthcare challenge, incurring significant costs and impacting patient quality of life. Current treatments often focus on passive management rather than actively promoting tissue regeneration and resolving underlying inflammation.
Solution
EVolution Therapeutics is developing exosome-based therapeutics designed to actively accelerate wound healing. The company leverages bio-active molecules derived from immunologically derived extracellular vesicles to target and modulate the inflammatory processes that impede healing. This approach aims to shift the treatment paradigm from passive wound care to active therapeutic intervention, promoting faster and more complete recovery for patients with chronic wounds and other inflammatory diseases. By harnessing the regenerative potential of exosomes, EVolution Therapeutics seeks to address unmet needs in wound management and improve patient outcomes.
Target Audience
The primary target audience includes patients with non-healing wounds, healthcare providers specializing in wound care, and organizations seeking advanced therapeutic solutions for inflammatory diseases.
Features
- Exosome-based therapeutics derived from immunologically active extracellular vesicles
- Targeted delivery of bio-active molecules to the wound site
- Modulation of inflammatory pathways to promote tissue regeneration
- Active therapeutic intervention for non-healing wounds